Rice University scientists Jeffrey Hartgerink, Brett Pogostin and Kevin McHugh have developed SABER, a peptide hydrogel system for drug delivery. Photos courtesy Rice University.

A team of Rice University scientists has developed a new drug delivery platform that researchers say can slow the rate of drug release, which has major implications for drug efficacy and potentially cancer immunotherapy.

The research was published in Nature Nanotechnology, and supported by the National Science Foundation, the National Institutes of Health, the Cancer Prevention and Research Institute of Texas and the Welch Foundation.

In the study, the team demonstrated how a peptide hydrogel functions as a three-dimensional network that controls the rate of release across a range of medication types, including small-molecule drugs and biologics such as insulin and antibodies. The system, called self-assembling boronate ester release (SABER), uses reversible chemical bonds between the peptide and the drug molecule to extend the duration of drug release. Instead of passing quickly through the net, the drug gets temporarily “stuck” each time it binds to the peptide, which slows its passage out of the hydrogel, according to Rice.

The researchers formulated a tuberculosis-treating drug into a hydrogel. They used it to treat infected mice with a single injection of the drug-laden hydrogel. In the test, the hydrogel outperformed almost daily oral administration of the medication over two weeks. Insulin packaged in SABER hydrogels successfully controlled blood sugar levels in diabetic mice for six days in another set of experiments.

Brett Pogostin, a Rice doctoral alum who led the development of SABER and served as first author of the study, began working on self-assembling peptides as an undergraduate student at Rice. Jeffrey Hartgerink, a professor of chemistry and bioengineering at Rice, and Kevin McHugh, associate professor of bioengineering and chemistry and a Cancer Prevention and Research Institute of Texas scholar, advised Pogostin and served as corresponding authors on the study.

Pogostin’s work aimed to bridge foundational materials research and biomedical applications. SABER was inspired by a drug delivery course taught by McHugh, where Pogostin learned about dynamic covalent bonds used in glucose sensing, where the bonds reversibly form and break apart. That quality inspired Pogostin to adapt the concept for drug delivery.

“Brett really drove this project in a way that is, in my experience, unusual for a graduate student,” Hartgerink said in the news release. “It’s a very versatile approach. You can make both small-molecule drugs and very large biologics sticky with the type of chemistry that Brett developed.”

The team demonstrated the platform in two different use cases with Tuberculosis and Type 1 diabetes, with SABER simplifying dosing and enhancing the efficacy of the drugs. Hartgerink described the current SABER system as “generation one,” and plans to work to make it widely applicable. He is looking into how SABER could be applied to cancer immunotherapy.

“What I’m really passionate about right now is cancer prevention — trying to think about how we can use materials to prime the immune system to prevent cancer from ever happening as opposed to just treating it,” Pogostin added.

From biomolecular research to oral cancer immunotherapy, here are three research projects to watch out for in Houston. Photo via Getty Images

These 3 Houston researchers are revolutionizing health science innovation

research roundup

Research, perhaps now more than ever, is crucial to expanding and growing innovation in Houston — and it's happening across the city right under our noses.

In InnovationMap's latest roundup of research news, a couple local scientists are honored by awards while another duo of specialists tackle a new project.

University of Houston professor recognized with award

Mehmet Orman of UH has been selected to receive an award for his research on persister cells. Photo via UH.edu

Mehmet Orman, assistant professor of chemical and biomolecular engineering at the University of Houston Cullen College of Engineering has been honored with a Faculty Early Career Development Award from the National Science Foundation. The award comes with a $500,000 grant to study persister cells — cells that go dormant and then become tolerant to extraordinary levels of antibiotics.

"Nearly all bacterial cultures contain a small population of persister cells," says Orman in a news release. "Persisters are thought to be responsible for recurring chronic infections such as those of the urinary tract and for creating drug-resistant mutants."

Previously, Orman developed the first methods to directly measure the metabolism of persister cells. He also developed cell sorting strategies to segregate persisters from highly heterogeneous bacterial cell populations, and, according to the release, he will be using his methods in the NSF research project.

Houston researchers collaborate on oral cancer innovation

Dr. Simon Young of UTHealth and Jeffrey Hartgerink of Rice University are working on a new use for an innovative gel they developed. Photo via Rice.edu

Two Houston researchers — chemist and bioengineer Jeffrey Hartgerink at Rice University and Dr. Simon Young at the University of Texas Health Science Center at Houston — have again teamed up to advance their previous development of a sophisticated hydrogel called STINGel. This time, they are using it to destroy oral cancer tumors.

SynerGel combines a pair of antitumor agents into a gel that can be injected directly into tumors. Once there, the gel controls the release of its cargo to not only trigger cells' immune response but also to remove other suppressive immune cells from the tumor's microenvironment. The duo reported on the technology in the American Chemical Society journal ACS Biomaterials Science & Engineering.

SynerGel, combines a pair of antitumor agents into a gel that can be injected directly into tumors, where they not only control the release of the drugs but also remove suppressive immune cells from the tumor's microenvironment.

"We are really excited about this new material," Hartgerink says in a news release. "SynerGel is formulated from a specially synthesized peptide which itself acts as an enzyme inhibitor, but it also assembles into a nanofibrous gel that can entrap and release other drugs in a controlled fashion.

In 2018, the pair published research on the use of a multidomain peptide gel — the original STINGel — to deliver ADU-S100, an immunotherapy drug from a class of "stimulator of interferon gene (STING) agonists."

The research is supported by the Oral and Maxillofacial Surgery Foundation, the National Institutes of Health, the Welch Foundation, the National Science Foundation and the Mexican National Council for Science and Technology.

Texas Heart Institute researcher honored by national organization

Dr. James Martin of Texas Heart Institute has been named a senior member of the National Academy of Inventors. Photo courtesy of THI

The National Academy of Inventors have named Houston-based Texas Heart Institute's Dr. James Martin, director of the Cardiomyocyte Renewal Lab, a senior member.

Martin is an internationally recognized developmental and regenerative biologist and his research is focused on understanding how signaling pathways are related to development and tissue regeneration.

"Dr. Martin has long been a steward of scientific advancement and has proven to be a tremendous asset to the Texas Heart Institute and to its Cardiomyocyte Renewal Lab through his efforts to translate fundamental biological discoveries in cardiac development and disease into novel treatment strategies for cardiac regeneration," says Dr. Darren Woodside, vice president for research at THI, in a news release. "Everyone at the Texas Heart Institute is thrilled for Dr. Martin, whose induction into the NAI as a Senior Member is well-deserved."

Martin has authored over 170 peer-reviewed papers in top journals he holds nine U.S. patents and applications, including one provisional application, all of which have been licensed to Yap Therapeutics, a company he co-founded.

The full list of incoming NAI Senior Members, which includes three professionals from the University of Houston, is available on the NAI website.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Innovative Houston-area hardtech startup closes $5M seed round

fresh funding

Conroe-based hardtech startup FluxWorks has closed a $5 million seed round.

The funding was led by Austin-based Scout Ventures, which invests in early-stage startups working to solve national security challenges.

Michigan Capital Network also contributed to the round from its MCN Venture Fund V. The fund is one of 18 selected by the Department of Defense and Small Business Administration to participate in the Small Business Investment Company Critical Technologies Initiative, which will invest $4 billion into over 1,700 portfolio companies.

FluxWorks reports that it will use the funding to drive the commercialization of its flagship Celestial Gear technology.

"At Scout, we invest in 'frontier tech' that is essential to national interest. FluxWorks is doing exactly that by solving critical hardware bottlenecks with its flagship Celestial Gear technology ... This is about more than just gears; it’s about strengthening our industrial infrastructure," Scout Ventures shared in a LinkedIn post.

Fluxworks specializes in making contactless magnetic gears for use in extreme conditions, which can enhance in-space manufacturing. Its contactless design leads to less wear, debris and maintenance. Its technology is particularly suited for space applications because it does not require lubricants, which can be difficult to control at harsh temperatures and in microgravity.

The company received a grant from the Texas Space Commission last year and was one of two startups to receive the Technology in Space Prize, funded by Boeing and the Center for the Advancement of Science in Space (CASIS), in 2024. It also landed $1.2 million through the National Science Foundation's SBIR Phase II grant this fall.

Fluxworks was founded in College Station by CEO Bryton Praslicka in 2021. Praslicka moved the company to Conroe 2024.

5 Houston scientists named winners of prestigious Hill Prizes 2026

prized research

Five Houston scientists were recognized for their "high-risk, high-reward ideas and innovations" by Lyda Hill Philanthropies and the Texas Academy of Medicine, Engineering, Science and Technology (TAMEST).

The 2026 Hill Prizes provide seed funding to top Texas researchers. This year's prizes were given out in seven categories, including biological sciences, engineering, medicine, physical sciences, public health and technology, and the new artificial intelligence award.

Each recipient’s institution or organization will receive $500,000 in direct funding from Dallas-based Lyda Hill Philanthropies. The organization has also committed to giving at least $1 million in discretionary research funding on an ad hoc basis for highly-ranked applicants who were not selected as recipients.

“It is with great pride that I congratulate this year’s Hill Prizes recipients. Their pioneering spirit and unwavering dedication to innovation are addressing some of the most pressing challenges of our time – from climate resilience and energy sustainability to medical breakthroughs and the future of artificial intelligence,” Lyda Hill, founder of Lyda Hill Philanthropies, said in a news release.

The 2026 Houston-area recipients include:

Biological Sciences: Susan M. Rosenberg, Baylor College of Medicine

Rosenberg and her team are developing ways to fight antibiotic resistance. The team will use the funding to screen a 14,000-compound drug library to identify additional candidates, study their mechanisms and test their ability to boost antibiotic effectiveness in animal models. The goal is to move toward clinical trials, beginning with veterans suffering from recurrent infections.

Medicine: Dr. Raghu Kalluri, The University of Texas MD Anderson Cancer Center

Kalluri is developing eye drops to treat age-related macular degeneration (AMD), the leading cause of vision loss globally. Kalluri will use the funding to accelerate studies and support testing for additional ocular conditions. He was also named to the National Academy of Inventors’ newest class of fellows last month.

Engineering: Naomi J. Halas, Rice University

Co-recipeints: Peter J. A. Nordlander and Hossein Robatjazi, Rice University

Halas and her team are working to advance light-driven technologies for sustainable ammonia synthesis. The team says it will use the funding to improve light-driven catalysts for converting nitrogen into ammonia, refine prototype reactors for practical deployment and partner with industry collaborators to advance larger-scale applications. Halas and Nordlander are co-founders of Syzygy Plasmonics, and Robatjazi serves as vice president of research for the company.

The other Texas-based recipients include:

  • Artificial Intelligence: Kristen Grauman, The University of Texas at Austin
  • Physical Sciences: Karen L. Wooley, Texas A&M University; Co-Recipient: Matthew Stone, Teysha Technologies
  • Public Health: Dr. Elizabeth C. Matsui, The University of Texas at Austin and Baylor College of Medicine
  • Technology: Kurt W. Swogger, Molecular Rebar Design LLC; Co-recipients: Clive Bosnyak, Molecular Rebar Design, and August Krupp, MR Rubber Business and Molecular Rebar Design LLC

Recipients will be recognized Feb. 2 during the TAMEST 2026 Annual Conference in San Antonio. They were determined by a committee of TAMEST members and endorsed by a committee of Texas Nobel and Breakthrough Prize Laureates and approved by the TAMEST Board of Directors.

“On behalf of TAMEST, we are honored to celebrate the 2026 Hill Prizes recipients. These outstanding innovators exemplify the excellence and ambition of Texas science and research,” Ganesh Thakur, TAMEST president and a distinguished professor at the University of Houston, added in the release. “Thanks to the visionary support of Lyda Hill Philanthropies, the Hill Prizes not only recognize transformative work but provide the resources to move bold ideas from the lab to life-changing solutions. We are proud to support their journeys and spotlight Texas as a global hub for scientific leadership.”

Investment bank opens new Houston office focused on energy sector

Investment bank Cohen & Co. Capital Markets has opened a Houston office to serve as the hub of its energy advisory business and has tapped investment banking veteran Rahul Jasuja as the office’s leader.

Jasuja joined Cohen & Co. Capital Markets, a subsidiary of financial services company Cohen & Co., as managing director, and head of energy and energy transition investment banking. Cohen’s capital markets arm closed $44 billion worth of deals last year.

Jasuja previously worked at energy-focused Houston investment bank Mast Capital Advisors, where he was managing director of investment banking. Before Mast Capital, Jasuja was director of energy investment banking in the Houston office of Wells Fargo Securities.

“Meeting rising [energy] demand will require disciplined capital allocation across traditional energy, sustainable fuels, and firm, dispatchable solutions such as nuclear and geothermal,” Jasuja said in a news release. “Houston remains the center of gravity where capital, operating expertise, and execution come together to make that transition investable.”

The Houston office will focus on four energy verticals:

  • Energy systems such as nuclear and geothermal
  • Energy supply chains
  • Energy-transition fuel and technology
  • Traditional energy
“We are making a committed investment in Houston because we believe the infrastructure powering AI, defense, and energy transition — from nuclear to rare-earth technology — represents the next secular cycle of value creation,” Jerry Serowik, head of Cohen & Co. Capital Markets, added in the release.

---

This article originally appeared on EnergyCaptialHTX.com.